Jim Simons Neurocrine Biosciences Inc Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,502,697 shares of NBIX stock, worth $335 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares

2,502,697

Previous 2,489,397 0.53%

Holding current value

$335 Million

Previous $340 Million 18.54%

% of portfolio

0.44%

Previous 0.54%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$107.22 - $153.29 $1.43 Million - $2.04 Million	13,300 Added 0.53%	2,502,697 $277 Million
Q4 2024 Feb 13, 2025	SELL	$111.62 - $139.44 $9.5 Million - $11.9 Million	-85,149 Reduced 3.31%	2,489,397 $340 Million
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $12.2 Million - $16.3 Million	106,400 Added 4.31%	2,574,546 $296 Million
Q2 2024 Aug 09, 2024	BUY	$130.86 - $143.19 $28.3 Million - $31 Million	216,500 Added 9.62%	2,468,146 $340 Million
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $34.3 Million - $37.8 Million	263,100 Added 13.23%	2,251,646 $311 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $42.3 Million - $52.9 Million	398,382 Added 25.05%	1,988,546 $262 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $5.01 Million - $6.23 Million	-53,238 Reduced 3.24%	1,590,164 $179 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $27.2 Million - $31.8 Million	-303,662 Reduced 15.6%	1,643,402 $155 Million
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $31.4 Million - $41 Million	333,400 Added 20.66%	1,947,064 $197 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $18.3 Million - $21.8 Million	171,200 Added 11.87%	1,613,664 $193 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $603,624 - $707,125	-6,559 Reduced 0.45%	1,442,464 $153 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $12.8 Million - $16.9 Million	168,900 Added 13.19%	1,449,023 $141 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $10.4 Million - $13.6 Million	-143,541 Reduced 10.08%	1,280,123 $120 Million
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $5.39 Million - $7.19 Million	67,700 Added 4.99%	1,423,664 $121 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $9.76 Million - $11.2 Million	113,241 Added 9.11%	1,355,964 $130 Million
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $13.9 Million - $15.9 Million	-155,141 Reduced 11.1%	1,242,723 $121 Million
Q1 2021 May 13, 2021	SELL	$87.57 - $119.4 $35.8 Million - $48.9 Million	-409,327 Reduced 22.65%	1,397,864 $136 Million
Q4 2020 Feb 10, 2021	SELL	$86.91 - $108.33 $29.7 Million - $37.1 Million	-342,273 Reduced 15.92%	1,807,191 $173 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $63.9 Million - $89.8 Million	664,700 Added 44.77%	2,149,464 $207 Million
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $65.1 Million - $99.8 Million	765,382 Added 106.39%	1,484,764 $181 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $1.49 Million - $2.25 Million	-19,790 Reduced 2.68%	719,382 $62.3 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $63.8 Million - $87.2 Million	735,272 Added 18853.13%	739,172 $79.5 Million
Q3 2019 Nov 13, 2019	SELL	$83.82 - $101.5 $950,602 - $1.15 Million	-11,341 Reduced 74.41%	3,900 $351,000
Q2 2019 Aug 12, 2019	SELL	$72.24 - $91.27 $15.4 Million - $19.4 Million	-212,700 Reduced 93.31%	15,241 $1.29 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $10.5 Million - $13.9 Million	152,100 Added 200.55%	227,941 $20.1 Million
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $5.18 Million - $9.43 Million	75,841 New	75,841 $5.42 Million

Others Institutions Holding NBIX

# of Institutions

649

Shares Held

96.9M

Call Options Held

800K

Put Options Held

565K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account